POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Study sponsor: Alumis Inc · ALMS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-08-13Actual
Enrollment · participants36Actual
Source updated2024-08-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.